Its values, its interview process and the questions it asks, in short episodes. Listen on a walk, then practice.
10 episodes1 free to try
No subscription needed
"Why AbbVie?" is the single most predictable question in any AbbVie interview — and the most commonly fumbled. Generic answers about "innovative medicines" and "patient impact" sound rehearsed and forgettable. This module shows candidates how to construct a specific, mission-grounded answer that draws on AbbVie's real strategic context — and stands out in a process where 64.6% of candidates pass the experience but only some get the offer.
In 2025, AbbVie announced a $10+ billion investment in U.S. manufacturing over the next decade — adding four new plants to its existing 11-site network and expanding active pharmaceutical ingredient (API) production. This module helps candidates understand AbbVie's industrial strategy, why it matters for the company's future, and how to talk about long-horizon thinking, scale, and quality in interviews — themes that map directly to the Decide Smart and Sure and Make Possibilities Real behavioral pillars.
AbbVie behavioral interviews cluster around a predictable set of themes: teamwork, cross-functional collaboration, conflict, failure, change, and decision-making under uncertainty. This module decodes the most common behavioral questions from Glassdoor reports, gives worked examples of strong STAR responses, and explains what hiring managers actually want to hear underneath the question.
AbbVie's interview process averages 31 days, scores 64.6% positive on Glassdoor, and varies dramatically by role — from a fast 12-day Specialty Representative process with a sales simulation, to a 40-day Senior Scientist process with a public seminar, to standardized panel interviews for corporate roles. This module gives candidates a clear-eyed map of what to expect, role by role, with honest signals about what the company is actually scoring.
Beyond "Ways We Work" (the behavioral framework, see Module 02), AbbVie also publishes five Principles that articulate its mission and values: Transforming Lives, Acting with Integrity, Driving Innovation, Embracing Diversity and Inclusion, and Serving the Community. This module decodes each principle, distinguishes it from "Ways We Work," and shows candidates how to weave them into authentic interview answers without sounding scripted.
In May 2020, AbbVie completed a $63 billion acquisition of Allergan — one of the largest pharma deals in history — transforming itself from an immunology-heavy company into a diversified biopharma spanning aesthetics, eye care, women's health, and neuroscience. This module explains the deal's strategic logic, the integration playbook AbbVie used, and what candidates can learn from it about how the company values cross-functional execution.
AbbVie has more than 90 drug and device programs in active development across immunology, oncology, neuroscience, eye care, and aesthetics — supported by 14,000 R&D staff across six centers of excellence in the U.S., Germany, and Japan. This module gives candidates the pipeline literacy to reference real programs by name, understand AbbVie's therapeutic strategy, and answer "what do you know about our science?" with substance.
Rob Michael became AbbVie's CEO in July 2024 and added the Chairman role on July 1, 2025 — making him the first Chair-CEO in the company's post-spin-off era. His finance-rooted, operationally rigorous leadership style is reshaping AbbVie's strategic priorities. This module helps candidates understand who Rob is, what he prioritizes, and what cultural signals to read from his first year — so they can speak credibly about the company's direction.
"Ways We Work" is AbbVie's five-pillar behavioral framework, rolled out shortly after the company's 2013 spin-off from Abbott. It's the lens every employee is annually evaluated against — and the internal grammar AbbVie interviewers use when scoring candidates. This module decodes each pillar, explains how it shows up in interview questions, and gives candidates the vocabulary to mirror it credibly.
In 2023, AbbVie faced the largest patent cliff in pharmaceutical history when Humira lost U.S. exclusivity — a drug that generated peak sales of over $21 billion annually. This module unpacks how AbbVie engineered a faster-than-expected recovery through Skyrizi and Rinvoq, why the story matters in interviews, and what it reveals about how AbbVie evaluates candidates' strategic thinking and resilience under pressure.